61 results about "Interleukin 6" patented technology

The invention discloses an anti-human inflammatory factor interleukin 6 monoclonal antibody and an application thereof. When the monoclonal antibody is prepared, an adopted immunogen is a human inflammatory factor interleukin 6 antigen, and an amino acid sequence of the human inflammatory factor interleukin 6 antigen comprises a sequence as shown in SEQ ID NO: 1. A group of monoclonal antibodies specifically combined with antigens is constructed based on the IL-6 antigens. The IL-6 monoclonal antibody has strong binding capacity with an IL-6 antigen in a clinical sample, has no cross reaction with other proteins, has good specificity and affinity compared with a commercial antigen, can be effectively applied to ELISA and a dry-type immunofluorescence method, has good detection linearity, precision, stability and accuracy, and can be widely applied to the field of immunoassay. The antibody can be combined with the antigen to serve as a detection reagent raw material combination, and has clinical detection advantages.

The invention belongs to the technical field of electrochemical sensors, and particularly relates to an in-situ self-amplification nucleic acid-based flexible wound sensor and a preparation method thereof. The sensor comprises a flexible substrate, a gold layer and a nucleic acid sensing layer, the nucleic acid sensing layer comprises a tumor necrosis factor-alpha sensor, an interleukin 6 sensor, a transforming growth factor beta1 sensor, a vascular endothelial growth factor sensor, a temperature sensor, a pH sensor, a reference electrode and a counter electrode; the tumor necrosis factor-alpha sensor, the interleukin 6 sensor, the transforming growth factor beta1 sensor and the vascular endothelial growth factor sensor are all modified with rigid DNA tetrahedrons with hairpin DNA H2 and corresponding hairpin DNA H1. The sensor provided by the invention has antifouling and anti-degradation effects; finally, in-situ nucleic acid amplification on the flexible biosensing interface is realized by virtue of a hydrophilic / hydrophobic confinement effect and an auxiliary nucleic acid pre-fixation strategy, so that the detection sensitivity is improved.

The present disclosure provides a method of identifying a tumor for immunotherapy. The method comprises culturing tumor cells obtained from a subject; exposing the tumor cells to nanoparticles comprising a positively-charged surface and an interior comprising (i) a core and (ii) at least two nucleic acid layers, wherein each nucleic acid layer is positioned between a cationic lipid bilayer; and measuring interferon-alpha and interleukin 6 (and optionally Chemokine (C-C motif) ligands 4) produced by the tumor cells. A method of treating a subject with cancer also is provided. The method comprises culturing tumor cells from the subject; exposing the tumor cells to the nanoparticles; measuring interferon-alpha and interleukin 6 (and optionally Chemokine (C-C motif) ligands 4) produced by the tumor cells; and administering an immune checkpoint inhibitor to the subject. Any of the methods may also comprise measuring CXCL 10.

The invention provides an application of phosphatidylcholine 36: 1 in prevention and treatment of senescence cognitive impairment, and particularly relates to an application of phosphatidylcholine 36: 1 or a pharmaceutical composition containing phosphatidylcholine 36: 1 in preparation of drugs for prevention and / or treatment of senescence cognitive impairment. The phosphatidylcholine 36: 1 can improve the level of superoxide dismutase and glutathione peroxidase in the brain of the mouse and reduce the lipid oxidation level at the same time. After the phosphatidylcholine 36: 1 is used for treatment, the levels of inflammatory factors interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in the brain are obviously reduced. Meanwhile, neurotransmitter disorder in brains of senescent mice can be remarkably improved. After qRT-PCR analysis is carried out in the brain of a mouse, it is found that after phosphatidylcholine 36: 1 treatment, the senescence gene level is remarkably reduced, the pro-apoptosis gene level is remarkably reduced, and the anti-apoptosis gene level is remarkably increased. And after in vitro administration of phosphatidylcholine 36: 1 to mouse hippocampal neuronal cells, no cytotoxicity is found. Therefore, the phosphatidylcholine 36: 1 can be used for preventing and treating senescence cognitive impairment.

The application discloses an electrochemical sensor for detecting IBD protein markers and a preparation method thereof. The electrochemical sensor is composed of a CNT-embedded semi-cured PDMS flexible substrate, deposited gold nanoparticles and a nucleic acid sensing layer. The nucleic acid sensing layer comprises a tumor necrosis factor-alpha sensor, an interleukin 6 sensor, an interleukin 8 sensor, a transforming growth factor beta 1 sensor, a reference electrode and a counter electrode. The tumor necrosis factor-alpha sensor, the interleukin 6 sensor, the interleukin 8 sensor and the transforming growth factor beta 1 sensor all adopt single-stranded aptamers modified by a signal molecule methylene blue, and the nucleotide sequences corresponding to the single-stranded aptamers are SEQ ID NO. 1-4. The application can improve the modulus matching of the sensor and human tissue and excellent biocompatibility, realize accurate detection of low-concentration biomarkers and stable signal output of the sensor under a strain working condition.

The present invention provides a primary cell culture medium for culturing primary lung cancer epithelial cells, which contains at least one of an MST1 / 2 kinase inhibitor, a ROCK kinase inhibitor, a fibroblast growth factor 7, a B27 supplement, and a N2 supplement, a hepatocyte growth factor, an insulin-like growth factor 1, an interleukin 6, and a TGFβ type I receptor inhibitor. The present invention also relates to a culturing method using the primary cell culture medium and its application in drug efficacy evaluation and screening. The culturing method uses the above-mentioned primary cell culture medium to culture primary cells on a culture vessel coated with extracellular matrix glue, so that the primary cells proliferate rapidly. The cell model obtained by the primary cell culture medium and the primary cell culturing method of the present invention can be used for drug efficacy evaluation and screening.

The invention provides a special culture medium for prostate cancer organoid and a culture method thereof, and belongs to the technical field of biological medicines. The special culture medium for the prostatic cancer organoid is composed of a basic culture medium and a culture additive, and the basic culture medium does not contain exogenously added Noggin recombinant protein and R-spondin recombinant protein. The culture additive is prepared from a basic fibroblast growth factor, a keratinocyte growth factor, a fibroblast growth factor 10, insulin, a p38MAPK signal channel inhibitor, an insulin-like growth factor 1, B27, nicotinamide, N-acetylcysteine, hydrocortisone, a ROCK kinase inhibitor, retinoic acid, interleukin 6, prostaglandin E2, a eriocin and androgen. According to the special culture medium for the prostatic cancer organoid, the culture success rate is increased while the cost is reduced.

The present invention provides a cell population and a method for obtaining the same. The cell population of the present invention is obtained by culturing mononuclear cells derived from bone marrow, umbilical cord blood or peripheral blood in a culture medium containing four or less factors selected from stem cell factor, interleukin 6, FMS-like tyrosine kinase 3 ligand, thrombopoietin and vascular endothelial cell growth factor, and serum.

The disclosure relates to the in vitro use of the combined (i) measure of MDM2-encoding DNA and (ii) measure of interleukin 6 protein, in platelets, or in extracellular vesicles carried by platelets, of a subject, as a biomarker indicative of the occurrence of a cancer having chromatin-bound MDM2 in the said subject.

Provided herein are methods for reducing risk of severe symptoms and outcomes associated with Coronavirus Disease 2019 (COVID-19) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection by measuring levels of interleukin 6 (IL-6), IL-8, IL-22, and serum ferritin in a subject. Also provided are methods for treating a subject exposed to or at elevated risk of expose to SARS-CoV-2 based on levels of IL-6, IL-8, IL-22, and ferritin in the serum of the subject.

The present invention discloses a recombinant nucleic acid molecule encoded by at least ORF (100, 100a) to reduce cytokine storm during immunotherapy. The recombinant nucleic acid molecule comprises at least one first hairpin ring structure, at least one second hairpin ring structure and a first promoter (120). The first hairpin loop structure is formed from one or more first short hairpin RNA (130a) sequences. The first hairpin ring structure modulates the amount of interleukin 6 (IL6) cytokine during immunotherapy. The second hairpin loop structure is formed from one or more second short hairpin RNA (130b) sequences. The second hairpin ring structure modulates the amount of granulocyte monocyte colony stimulating factor (GMCSF) cytokine during immunotherapy and is disposed upstream or downstream of the first hairpin ring structure. The first promoter (120) is disposed upstream of the first hairpin ring structure and the second hairpin ring structure.

The disclosure provides methods of preventing or treating heart failure in a mammalian subject, reducing risk factors associated with heart failure, and / or reducing the likelihood or severity of heart failure. The disclosure also provides methods of preventing, or treating LV remodeling in a mammalian subject, and / or reducing the likelihood or severity of LV remodeling. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide. In some embodiments, the methods comprise administering to the subject an effective amount of an aromatic cationic peptide to reduce levels of C-reactive protein, tumor necrosis factor alpha, interleukin 6, reactive oxygen species, Nt-pro BNP, and / or cardiac troponin I, and / or reduce expression levels of MLCL AT1 and / or ALCAT 1 in subjects in need thereof.

The invention discloses a kit for detecting susceptibility and severity of children acute respiratory distress syndrome, and relates to the technical field of biomedical detection. The kit comprises a detection reagent combination and a standardized reference system, the detection reagent combination is prepared from specific binding angiogenin 2, a soluble advanced glycosylation end product receptor, pulmonary surfactant protein D, a soluble tumor necrosis factor receptor 1, interleukin 6, interleukin 8, a plasminogen activator inhibitor 1 and a capture and detection antibody of III type procollagen N-terminal peptide. The primer pair and the probe are used for specifically amplifying a single nucleotide polymorphism site rs4073 in a promoter region of the interleukin 8 gene; the standardized reference product system comprises gradient standard products covering the physiological concentration dynamic ranges of the markers on the 0th day, the 3rd day and the 7th day of morbidity; the kit is used for early-stage precise layering and dynamic prognosis evaluation of the acute respiratory distress syndrome of children.

The subject matter described herein relates to peptides that bind to the human AT-rich interactive domain 5A protein (Arid5a). The subject matter described herein also relates to methods of inhibiting Interleukin 6 (IL-6) production in a subject, the method comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of any one of the peptides disclosed herein.

A recombinant nucleic acid molecule is encoded at least by an ORF to lower a cytokine storm during immunotherapy. The recombinant nucleic acid molecule includes at least one hairpin loop structure and a first promoter. The at least one hairpin loop structure is formed by one or more short hairpin RNA sequences. The at least one hairpin loop structure regulates an amount of Interleukin 6 (IL6) cytokine during immunotherapy. The first promoter is disposed upstream of the at least one hairpin loop structure.

The disclosure relates to the in vitro use of the combined (i) measure of MDM2-encoding DNA and (ii) measure of interleukin 6 protein, in platelets, or in platelet-derived extracellular vesicles, of a subject, as a biomarker indicative of the occurrence of a cancer having chromatin-bound MDM2 in the said subject.

The present invention discloses a recombinant nucleic acid molecule encoded by at least ORFs (100, 100a) for reducing cytokine storm during immunotherapy. The recombinant nucleic acid molecule comprises at least one hairpin loop structure and a first promoter (120). The at least one hairpin loop structure is formed by one or more short hairpin RNA (130) sequences. The at least one hairpin loop structure regulates the amount of interleukin 6 (IL6) cytokine during immunotherapy. The first promoter (120) is located upstream of the at least one hairpin loop structure.

This invention provides an antibody combination for detecting interleukin-6 (IL-6), comprising a first antibody and / or a second antibody, each possessing a unique CDR fragment. Specific applications of this antibody combination are also provided. The advantages of this invention are that the antibody combination exhibits strong affinity for the IL-6 antigen, high detection sensitivity, ease of use, and rapid and stable detection. The concentration of IL-6 in normal human blood is approximately 4.2 pg / mL. Existing conventional low-affinity antibodies are insufficient for effective detection in this situation. However, the high-affinity antibody combination and the IL-6 quantitative detection kit containing this antibody combination using a double-antibody sandwich method provided by this invention can effectively achieve the quantitative detection of ultra-low concentrations of IL-6. Verification shows that the kit's sensitivity can reach 0.9 pg / mL.

The application discloses a kit for detecting interleukin 6 and preparation and application. The kit comprises magnetic microspheres coated first antibodies and tracer marker labeled second antibodies. The first antibodies are 12H6 with a catalog number of DA011, IL-6-55E9 with a catalog number of P1810035 of Jin Sui, or IL-6-01 with a catalog number of 20180915 of Gelin. The second antibodies are 15H5 with a catalog number of DA012, IL-6-55C6 with a catalog number of P1904008 of Jin Sui, or IL-6-02 with a catalog number of 20180919 of Gelin. The application has the advantages of simple operation, low cost, short detection time, high sensitivity and wide linear range, and can realize full-automatic, rapid, sensitive and quantitative detection of the concentration of IL-6 in samples.

The invention provides a composition for improving bone joints and promoting bone health as well as a preparation method and application thereof, and relates to the technical field of compositions. The composition is prepared from N-acetylglucosamine and a turmeric extract. The composition can improve the differentiation activity of cartilage precursor cells, effectively promote synthesis of cartilage matrixes, increase the structural construction ability of cartilage tissues, reverse expression down-regulation of cartilage synthesis markers, down-regulate abnormally high expression of cartilage decomposition markers and maintain metabolic balance of cartilage synthesis and decomposition, and has the effects of improving the cartilage tissue differentiation activity and improving the cartilage tissue differentiation activity. Abnormal high secretion of tumor necrosis factors alpha and interleukin 6 in LPS-induced cartilage cells is reduced, and the effects of resisting inflammation, resisting cartilage degradation and maintaining cartilage metabolism balance are achieved.

A recombinant nucleic acid molecule is encoded at least by an ORF to lower a cytokine storm during immunotherapy. The recombinant nucleic acid molecule includes at least one hairpin loop structure and a first promoter. The hairpin loop structure regulates an amount of Interleukin 6 (IL6) cytokine during immunotherapy. The hairpin loop structure is formed by at least two short hairpin RNA sequences and at least one microRNA30 sequence. The short hairpin RNA sequences form a stem of the hairpin loop structure. The microRNA30 sequence forms a loop of the hairpin loop structure. The first promoter is disposed upstream of the hairpin loop structure.

The invention discloses a sea cucumber peptide applied to auxiliary protection of acute gastric mucosal lesion and a preparation method thereof, and relates to the technical field of biological peptides, and the preparation method comprises the following steps: step 1, taking fresh sea cucumbers, and sequentially carrying out cleaning, acid-base soaking for ash removal and pulping treatment to obtain ground sea cucumber pulp; step 2, boiling the ground sea cucumber slurry at constant temperature and constant pressure, cooling to 55 DEG C, and performing enzymolysis by multiple compound enzymes to obtain enzymatic hydrolysate; step 3, heating the enzymatic hydrolysate to 85 DEG C and carrying out enzyme deactivation treatment for 5 minutes to obtain a protein peptide mixed solution; and 4, separating the protein peptide, and drying to obtain the sea cucumber peptide particles. The sea cucumber peptide applied to auxiliary protection of acute gastric mucosal lesion is obtained, it is detected that interleukin 1 beta (IL-1beta), interleukin 6 (IL-6), pepsinogen 1 (PG1), pepsinogen 2 (PG2) and tumor necrosis factor alpha (TNF-alpha) in rat serum have significant differences from a control group, and the purpose of auxiliary protection of acute gastric mucosal lesion is achieved.

The invention discloses an application of hydrogen-rich water in improving chronic aluminum exposure mouse injury. The injury caused by chronic aluminum exposure comprises at least one of nerve injury, liver and kidney injury, intestinal barrier injury and blood brain barrier injury. The product is a beverage, a health care product or a medicine. The improvement effect is realized by adjusting a microorganism-intestinal-brain axis, including up-regulating the abundance of beneficial bacteria in the intestinal tract; the level of anti-inflammatory metabolites baicalein and indole-3-ethanol is increased, and the expression of inflammatory factors interleukin 6, interleukin 1 beta and tumor necrosis factor a is reduced; inflammation and oxidative stress reaction caused by chronic aluminum exposure can be remarkably relieved through hydrogen-rich water intervention, and meanwhile the liver and kidney functions can be effectively improved. In addition, abnormal behaviors of chronic aluminum exposure mice are improved, and the level of beta-amyloid protein in brains of the mice is remarkably reduced; the hydrogen-rich water is prompted to improve the abundance of beneficial bacteria, so that the bacteria have a protection effect on the organism with chronic aluminum exposure through the effects of resisting oxidation, resisting inflammation, protecting nerves and the like.

Disclosed in the present invention are antifungal compounds, a preparation method therefor, and the use thereof. The compounds have the following general formula I, wherein L represents a linking moiety, referring to a small molecule fragment, and Ar represents a heterocyclic ring or a substituted heterocyclic ring. The series of compounds of the present invention can better bind to an enzyme target by means of various interaction forces, thereby exhibiting good activity; and the compounds exhibit excellent activity in both in vitro experiments and animal experiments, the activity of most of the compounds against Candida albicans being better than that of fluconazole. In addition, the series of compounds have anti-inflammatory effects while eliminating fungal infections; and compared with voriconazole, the series of compounds of the present invention can remarkably down-regulate the expression of an inflammatory factor interleukin 6.

This document provides methods and materials for assessing and / or treating mammals (e.g., humans) having, or suspected of having, a spinal cord injury. For example, the presence of (a) spinal cord-derived cell free DNA (cfDNA) and / or (b) an elevated level of one or more of a fatty acid binding protein 3 (FABP3) polypeptide, a RE1-silencing transcription factor (REST) polypeptide, an interleukin 6 (IL-6) polypeptide, and a neurofilament, heavy polypeptide (NF-H) polypeptide in a fluid sample (e.g., a blood sample) obtained from a mammal (e.g., a human) can be used to identify that mammal as having a spinal cord injury. In some cases, a mammal (e.g., a human) identified as having a spinal cord injury as described herein can be administered one or more spinal cord injury treatments.

The present invention discloses a recombinant nucleic acid molecule encoded by at least ORF (100, 100a) to reduce cytokine storm during immunotherapy. The recombinant nucleic acid molecule comprises at least one hairpin ring structure and a first promoter (120). The at least one hairpin ring structure is formed from one or more short hairpin RNA (130) sequences. The at least one hairpin ring structure modulates the amount of interleukin 6 (IL6) cytokine during immunotherapy. The first promoter (120) is disposed upstream of the at least one hairpin ring structure.

The invention provides a cell population and a method for obtaining the same. A cell population according to the present invention is obtained by culturing mononuclear cells derived from bone marrow, umbilical cord blood or peripheral blood in a culture medium containing serum and four or less factors selected from the group consisting of stem cell factors, interleukin 6, FMS-like tyrosine kinase 3 ligand, thrombopoietin, and vascular endothelial cell growth factors.

The invention discloses an electrochemical sensor for IBD protein marker detection as well as a preparation method and application of the electrochemical sensor. The electrochemical sensor is composed of a semi-cured PDMS flexible substrate in which CNT is embedded, deposited gold nanoparticles and a nucleic acid sensing layer, the nucleic acid sensing layer comprises a tumor necrosis factor-alpha sensor, an interleukin 6 sensor, an interleukin 8 sensor, a transforming growth factor beta1 sensor, a reference electrode and a counter electrode; the tumor necrosis factor-alpha sensor, the interleukin 6 sensor, the interleukin 8 sensor and the transforming growth factor beta1 sensor all adopt aptamer single chains modified by signal molecule methylene blue, and correspondingly adopt nucleotide sequences shown in SEQ ID NO.1-4. Matching and excellent biocompatibility of the sensor and human tissue modulus can be improved, and accurate detection of low-concentration biomarkers and stable signal output of the sensor under the strain working condition are achieved.

The present invention relates to compositions for detecting a lung cancer disease, comprising peptide affinity ligands for detecting different combinations of proteins of different groups of biomarkers which include CYFRA 21-1, Prolactin, Squamous Cell Carcinoma Antigen (SCC), Her2 / Neu, Cancer antigen 125 (CA125), carcinoembryonic antigen (CEA), C- reactive protein (CRP), Neuron Specific Enolase (NSE), C4 complement (C4), Interleukin 6 (IL-6), and Metallopeptidase Inhibitor 1 (TIMP-1). The invention further relates to methods of detecting or subtyping lung diseases, as well as to computer-implemented methods based on machine learning methods using expression data of the biomarkers.

The invention relates to the field of biological pharmacy, in particular to application of a regulatory factor inhibitor in preparation of a medicine for treating scapulohumeral periarthritis, and the regulatory factor inhibitor is used for inhibiting expression of interleukin 6 and / or inhibiting expression of matrix metalloproteinase 2 and matrix metalloproteinase 9. By inhibiting the expression of the regulatory factors, the activity of M1 type macrophages is inhibited, the activity of M2 type macrophages is not influenced, the development of inflammation is inhibited through an immune system, and the anti-inflammatory effect is improved.